Octreotide

also known as Octreotide Acetate · Octreotide LAR · Sandostatin LAR · Sandostatin LAR Depot · Sandostatin · octLAR · Long-acting octreotide · OCT · +21 more

Peptide

Developed for: acromegaly · diarrheal disease · neuroendocrine neoplasm · autosomal dominant polycystic kidney disease · cirrhosis of liver · diabetic retinopathy · digestive system neuroendocrine neoplasm · hepatocellular carcinoma
+73 more
· hepatorenal syndrome · carcinoid syndrome · intestinal obstruction · neuroendocrine carcinoma · obesity disorder · pancreas disorder · prostate cancer · cancer · esophageal varices · esophageal varices with bleeding · gastric cancer · hereditary hemorrhagic telangiectasia · HIV infectious disease · hypoglycemia · liver disorder · pancreatic endocrine carcinoma · pancreatic neoplasm · Prader-Willi syndrome · acquired hypothalamic obesity · adenoma · anemia · autonomic nervous system disorder · breast cancer · cancer of unknown primary site · carcinoid tumor · cardiac rhythm disease · chemotherapy-induced toxicity · colorectal neuroendocrine tumor G1 · combined thymoma · congenital isolated hyperinsulinism · constipation disorder · cysts and fistulae of the face and oral cavity · digestive system carcinoma · digestive system neuroendocrine tumor, grade 1/2 · endocrine pancreas disorder · enteritis · esophageal cancer · esophageal neuroendocrine tumor · female breast carcinoma · gastric neuroendocrine tumor G1 · glucose intolerance · idiopathic pulmonary fibrosis · intestinal neuroendocrine neoplasm · irritable bowel syndrome · kidney failure · liver cancer · lymphangioleiomyomatosis · lymphangiomyoma · lymphoma · meningioma · metastatic malignant neoplasm · migraine disorder · multiple endocrine neoplasia · obesity, hyperphagia, and developmental delay · orthostatic hypotension · pancreatic gastrinoma · pancreatic neuroendocrine tumor · pancreatic neuroendocrine tumor G1 · peritoneal carcinomatosis · portal hypertension · proliferative diabetic retinopathy · respiratory tract neoplasm · thymoma · thymus neoplasm · VIPoma · angiodysplasia · autosomal dominant polycystic liver disease · carcinoma · diabetic macular edema · impaired renal function disease · pituitary gland adenoma · varicose disease · vascular malformation
Investigated by: Novartis Pharmaceuticals · Novartis · National Cancer Institute (NCI) · Camurus AB · Federico II University · Aspireo Pharmaceuticals Limited
+140 more
· University of Aarhus · Alliance for Clinical Trials in Oncology · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Eastern Cooperative Oncology Group · Endo USA Inc., a Keenova Therapeutics Company · Mario Negri Institute for Pharmacological Research · Aarhus University Hospital · Chiasma, Inc. · Duke University · Göteborg University · Indiana University · Karolinska University Hospital · National Center for Research Resources (NCRR) · National Hepatology & Tropical Medicine Research Institute · Odense University Hospital · Peking University · Pfizer · Radboud University Medical Center · Rigshospitalet, Denmark · Sandoz · St. James's Hospital, Ireland · University College Dublin · University of Dublin, Trinity College · University of Turin, Italy · Aalborg University Hospital · Aarhus University Hospital Skejby · Academic Medical Center - University of Amsterdam · Advanced Accelerator Applications · AdventHealth · Albert Einstein Healthcare Network · Ambrilia Biopharma, Inc. · Anna Cruceta · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Assistance Publique Hopitaux De Marseille · Azidus Brasil · Azienda Ospedaliera Universitaria Integrata Verona · Azienda Ospedaliera di Padova · Bispebjerg Hospital · Bryan Schneider, MD · C.R.Darnall Army Medical Center · Cancer and Leukemia Group B · Carmen Schade-Brittinger · Catharina Ziekenhuis Eindhoven · Cedars-Sinai Medical Center · Centre Hospitalier Universitaire, Amiens · Changhai Hospital · Chemi S.p.A. · Chengfeng Wang · Clinica Universidad de Navarra, Universidad de Navarra · Clinical Cancer Hospital, Kyiv · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Columbia University · Copenhagen University Hospital, Denmark · Danbury Hospital · Dauntless Pharmaceuticals · Debiopharm International SA · Deutsche Krebshilfe e.V., Bonn (Germany) · Erasmus Medical Center · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Fox Chase Cancer Center · French National Institute of Health and Medical Research · Genentech, Inc. · German Federal Ministry of Education and Research · H. Lee Moffitt Cancer Center and Research Institute · Hadassah Medical Organization · Helsinki University Central Hospital · Herlev Hospital · Hoosier Cancer Research Network · Ipsen · Isala · Jeroen Bosch Hospital · Juan A. Arnaiz · Karolinska University Hospital · all 146 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Mycapssa	—	2022-12-02	europa.eu ↗
Label expansions (2)	US (FDA)	SANDOSTATIN LAR	—	2006-05-10 – 2008-03-03	fda.gov ↗
Label expansion	US (FDA)	SANDOSTATIN	—	1994-05-03	fda.gov ↗
Approved	US (FDA)	SANDOSTATIN	—	1988-10-21	fda.gov ↗

Trials 148 · started per year

today

US approved 1988

EU approved 2022

19881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT05683444	Jul 2020 → Mar 2021	lymphatic system disorder	Rigshospitalet, Denmark	Completed	No outcome recorded
Phase 113 trials
Phase 1	NCT05761431	Mar → Jun 2023	acromegaly	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05340192	Sep 2019 → Feb 2020	—	Duke University	Completed	No outcome recorded
Phase 1	NCT03798912	Jul 2019 → Feb 2020	—	RANI Therapeutics	Completed	No outcome recorded
Phase 1	NCT03031535	Jan → Mar 2017	—	Dauntless Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02195635	Jul → Oct 2014	—	Lexicon Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01707225	Feb 2013 → Oct 2014	—	Virginia Commonwealth University	Completed	No outcome recorded
Phase 1	NCT02217839	Apr 2012 → Jan 2013	—	Aspireo Pharmaceuticals Limited	Completed	No outcome recorded
Phase 1	NCT01086982	Mar → May 2010	acromegaly	Azidus Brasil	Suspended	No outcome recorded
Phase 1	NCT00584298	Jan 2008 → Apr 2009	irritable bowel syndrome	Novartis	Completed	No outcome recorded
Phase 1	NCT00432068	Jan 2007 → Jun 2010	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00223691	Mar 2002 → Jan 2017	autonomic nervous system disorder, orthostatic hypotension	Vanderbilt University	Completed	No outcome recorded
Phase 1	NCT00008073	Jan 1996 → May 2002	cancer of unknown primary site	University of Pittsburgh	Completed	No outcome recorded
Phase 1	NCT02217826	? → Apr 2014	—	Aspireo Pharmaceuticals Limited	Completed	No outcome recorded

Phase 1/25 trials
Phase 1/2	NCT00884715	Jul 2009 → Nov 2011	carcinoid syndrome	Endo USA Inc., a Keenova Therapeutics Company	Terminated	No outcome recorded
Phase 1/2	NCT00463983	Oct 2006 → Jan 2010	idiopathic pulmonary fibrosis	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 1/2	NCT00274170	Jan 2006 → Feb 2007	migraine disorder	C.R.Darnall Army Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT01188733	Jun 1998 → Jul 2000	cirrhosis of liver, esophageal varices, portal hypertension	Mayo Clinic	Completed	No outcome recorded
Phase 1/2	NCT00262470	Apr 1997 → Dec 2029 expected	cardiac rhythm disease	Satish R. Raj	Active not recruiting	No outcome recorded
Phase 246 trials
Phase 2	NCT06085976	Aug 2023 → Aug 2025	hepatocellular carcinoma	Clinica Universidad de Navarra, Universidad de Navarra	Unknown	No outcome recorded
Phase 2	NCT04871204	Jun 2021 → Feb 2024	esophageal cancer, gastric cancer	Karolinska University Hospital	Completed	No outcome recorded
Phase 2	NCT04027348	Jun 2019 → Sep 2021	intestinal obstruction	Roswell Park Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT03541447	Dec 2018 → Dec 2021	autosomal dominant polycystic kidney disease	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 2	NCT03179995	Jul 2017 → Feb 2020	—	Fox Chase Cancer Center	Terminated	No outcome recorded
Phase 2	NCT04129255	Jun 2017 → Dec 2019	neuroendocrine neoplasm	National Cancer Institute, Naples	Completed	No outcome recorded
Phase 2	NCT02874326	Oct 2016 → Jul 2018	anemia, hereditary hemorrhagic telangiectasia	Radboud University Medical Center	Unknown	No outcome recorded
Phase 2	NCT02916433	Sep 2016 → Feb 2018	—	Danbury Hospital	Completed	No outcome recorded
Phase 2	NCT01587222	Jul 2016 → Jul 2017	hepatorenal syndrome, kidney failure	Anna Cruceta	Withdrawn	No outcome recorded
Phase 2	NCT02668588	Oct 2015 → Jul 2016	—	Chemi S.p.A.	Completed	No outcome recorded
Phase 2	NCT02437825	Oct 2015 → Jun 2021	cysts and fistulae of the face and oral cavity	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 2	NCT02409849	Apr 2015 → Nov 2018	digestive system carcinoma, esophageal neuroendocrine tumor	Peking University	Unknown	No outcome recorded
Phase 2	NCT02333565	Jan 2015 → Jan 2019	meningioma	Assistance Publique Hopitaux De Marseille	Completed	No outcome recorded
Phase 2	NCT02299089	Jan 2015 → May 2016	acromegaly, neuroendocrine neoplasm	Camurus AB	Completed	No outcome recorded
Phase 2	NCT02294786	Dec 2014 → Oct 2017	cancer	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT02294006	Jun 2014 → Jun 2021	pancreatic neuroendocrine tumor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Unknown	No outcome recorded
Phase 2	NCT02101385	Apr 2014 → Feb 2021	breast cancer	Bryan Schneider, MD	Completed	No outcome recorded
Phase 2	NCT01886287	Dec 2013 → Aug 2014	neuroendocrine carcinoma	H. Lee Moffitt Cancer Center and Research Institute	Terminated	No outcome recorded
Phase 2	NCT02217800	Nov 2013 → Mar 2014	acromegaly	Aspireo Pharmaceuticals Limited	Completed	No outcome recorded
Phase 2	NCT02235987	Oct → Dec 2012	acromegaly	Aspireo Pharmaceuticals Limited	Completed	No outcome recorded
Phase 2	NCT01469338	Jul 2012 → Oct 2014	diarrheal disease, hormone-resistant prostate carcinoma	University of Southern California	Terminated	No outcome recorded
Phase 2	NCT01480986	Sep 2011 → Sep 2012	—	Peking University	Completed	No outcome recorded
Phase 2	NCT01567488	Jun 2011 → Sep 2014	digestive system neuroendocrine neoplasm	Spanish Group for Research in Neuroendocrine Tumors	Completed	No outcome recorded
Phase 2	NCT01229943	Oct 2010 → Sep 2014	VIPoma, pancreatic gastrinoma, pancreatic neuroendocrine tumor G1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01121939	May 2010 → Feb 2015	neuroendocrine carcinoma	SCRI Development Innovations, LLC	Completed	No outcome recorded
Phase 2	NCT00987168	May 2009 → Apr 2011	congenital isolated hyperinsulinism	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT00510224	Jul 2007 → Aug 2009	prostate cancer	University of California, San Francisco	Terminated	No outcome recorded
Phase 2	NCT00913055	Feb → May 2007	acromegaly	Endo USA Inc., a Keenova Therapeutics Company	Completed	No outcome recorded
Phase 2	NCT00990535	Jan 2006 → Dec 2007	multiple endocrine neoplasia, pancreatic neoplasm, respiratory tract neoplasm, thymus neoplasm	Federico II University	Completed	No outcome recorded
Phase 2	NCT01203306	Jan 2006 → May 2009	neuroendocrine carcinoma	University of Turin, Italy	Unknown	No outcome recorded
Phase 2	NCT00332969	Sep 2005 → Oct 2010	thymoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00332696	Sep 2005 → Sep 2008	intestinal obstruction, peritoneal carcinomatosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00257426	Jul 2005 → Feb 2007	liver cancer	UNC Lineberger Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00113360	Jan 2005 → Jul 2009	pancreatic endocrine carcinoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00088582	Mar 2004 → Oct 2005	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00166725	Feb 2004 → ?	prostate cancer	Novartis	Completed	No outcome recorded
Phase 2	NCT00953394	Feb 2002 → Feb 2006	neuroendocrine neoplasm	University of Turin, Italy	Completed	No outcome recorded
Phase 2	NCT00094146	Jan → Dec 2002	endocrine pancreas disorder, obesity disorder	Novartis	Completed	No outcome recorded
Phase 2	NCT00250796	Sep 2000 → Jan 2006	cancer, liver disorder	University of New Mexico	Completed	No outcome recorded
Phase 2	NCT00005906	Jun 2000 → Apr 2008	lymphangioleiomyomatosis, lymphangiomyoma	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00004895	Oct 1999 → Oct 2002	bile duct cancer, colorectal cancer, gastric cancer, gastrointestinal stromal tumor +5	Northwestern University	Completed	No outcome recorded
Phase 2	NCT00001860	Aug 1999 → Jul 2002	acromegaly, pituitary tumor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00003283	Oct 1998 → Sep 2003	combined thymoma	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 2	NCT00002779	Feb 1998 → Jul 2000	lymphoma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00004327	Jan 1995 → ?	hereditary hemorrhagic telangiectasia	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2	NCT00227773	—	carcinoid tumor, pancreatic endocrine carcinoma	Eastern Cooperative Oncology Group	Withdrawn	No outcome recorded

Phase 2/38 trials
Phase 2/3	NCT07165886	Aug 2025 → Aug 2028 expected	digestive system neuroendocrine neoplasm	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Recruiting	No outcome recorded
Phase 2/3	NCT06062719	Aug 2023 → Sep 2024	—	National Hepatology & Tropical Medicine Research Institute	Unknown	No outcome recorded
Phase 2/3	NCT05281328	Jun 2022 → Feb 2025 overdue	liver disorder	Camurus AB	Active not recruiting	No outcome recorded
Phase 2/3	NCT02119013	Jan 2009 → Sep 2013	autosomal dominant polycystic kidney disease	Federico II University	Completed	No outcome recorded
Phase 2/3	NCT02119052	Jan 2009 → Sep 2013	autosomal dominant polycystic kidney disease	Federico II University	Completed	No outcome recorded
Phase 2/3	NCT00495846	Apr 2007 → Apr 2008	hepatocellular carcinoma	Federico II University	Completed	No outcome recorded
Phase 2/3	NCT00240045	Oct 2005 → Jul 2007	hepatorenal syndrome	University of Alberta	Completed	No outcome recorded
Phase 2/3	NCT00742339	May 2005 → Oct 2013	cirrhosis of liver, hepatorenal syndrome	University of Padova	Terminated	No outcome recorded
Phase 335 trials
Phase 3	NCT07623824	May 2026 → Jul 2029 expected	acromegaly	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT06930625	Nov 2025 → Jun 2028 expected	acromegaly	Debiopharm International SA	Recruiting	No outcome recorded
Phase 3	NCT06784752	May 2025 → Dec 2028 expected	digestive system neuroendocrine neoplasm	Novartis Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT05050942	Oct 2021 → Jul 2026 overdue	digestive system neuroendocrine neoplasm	Camurus AB	Active not recruiting	No outcome recorded
Phase 3	NCT04125836	Oct 2019 → Apr 2025	acromegaly	Camurus AB	Completed	No outcome recorded
Phase 3	NCT04076462	Aug 2019 → May 2023	acromegaly	Camurus AB	Completed	No outcome recorded
Phase 3	NCT02685709	Feb 2016 → Oct 2020	acromegaly	Chiasma, Inc.	Completed	No outcome recorded
Phase 3	NCT01578239	Sep 2012 → Jul 2015	intestinal neuroendocrine neoplasm	Advanced Accelerator Applications	Completed	No outcome recorded
Phase 3	NCT01412424	Mar 2012 → May 2014	acromegaly	Chiasma, Inc.	Completed	No outcome recorded
Phase 3	NCT01377246	May 2011 → Oct 2017	autosomal dominant polycystic kidney disease	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 3	NCT01295060	Feb 2011 → Apr 2012	acromegaly	Endo USA Inc., a Keenova Therapeutics Company	Terminated	No outcome recorded
Phase 3	NCT00582426	Apr 2008 → Sep 2010	chemotherapy-induced toxicity	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00569127	Dec 2007 → Jan 2015 overdue	colorectal neuroendocrine tumor G1, gastric neuroendocrine tumor G1	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 3	NCT00635765	Oct 2007 → Jun 2009	acromegaly	Ambrilia Biopharma, Inc.	Completed	No outcome recorded
Phase 3	NCT00309283	Apr 2006 → Jan 2012	autosomal dominant polycystic kidney disease	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 3	NCT00372697	Dec 2005 → Oct 2007	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00248157	Nov 2005 → May 2006	diabetic retinopathy	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00248131	Nov 2005 → Jul 2006	diabetic retinopathy	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00182754	Oct 2005 → Sep 2009	metastatic malignant neoplasm	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 3	NCT00804297	Jun 2005 → Jan 2007	diabetes mellitus, hypoglycemia	Albert Einstein Healthcare Network	Completed	No outcome recorded
Phase 3	NCT00175305	Aug 2004 → Oct 2007	Prader-Willi syndrome, obesity, hyperphagia, and developmental delay	University of British Columbia	Terminated	No outcome recorded
Phase 3	NCT00092287	Jul → Oct 2004	carcinoid syndrome	Ipsen	Terminated	No outcome recorded
Phase 3	NCT00170742	Dec 2003 → May 2006	proliferative diabetic retinopathy	Novartis	Terminated	No outcome recorded
Phase 3	NCT00075868	Dec 2003 → Aug 2006	anus cancer, enteritis	Radiation Therapy Oncology Group	Completed	No outcome recorded
Phase 3	NCT00128232	Dec 2002 → Aug 2004	acromegaly	Novartis	Completed	No outcome recorded
Phase 3	NCT00225979	Nov 2002 → Mar 2005	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00241020	Jun 2002 → Oct 2005	hepatocellular carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00033605	Apr 2002 → Jul 2006	cervical cancer, colorectal cancer, diarrheal disease, endometrial cancer +6	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 3	NCT00171873	Sep 2001 → Jun 2008	neuroendocrine neoplasm	Carmen Schade-Brittinger	Completed	No outcome recorded
Phase 3	NCT00130845	Feb 2000 → Dec 2005	diabetic retinopathy	Novartis	Completed	No outcome recorded
Phase 3	NCT00006269	Dec 1999	colorectal cancer, diarrheal disease	Novartis	Terminated	No outcome recorded
Phase 3	NCT00131144	Nov 1999 → Dec 2005	diabetic retinopathy	Novartis	Completed	No outcome recorded
Phase 3	NCT00386984	Oct 1999 → Feb 2003	hepatocellular carcinoma	University Hospital Freiburg	Completed	No outcome recorded
Phase 3	NCT00002967	May 1997 → Mar 2006	female breast carcinoma	NSABP Foundation Inc	Completed	No outcome recorded
Phase 3	NCT00003057	Mar 1997 → May 2000	colorectal cancer, diarrheal disease	Eastern Cooperative Oncology Group	Completed	No outcome recorded

Phase 426 trials
Phase 4	NCT07262957	Sep 2025 → Sep 2027 expected	ampulla of vater adenocarcinoma, cholangiocarcinoma, cystic neoplasm, neuroendocrine neoplasm +3	Academic Medical Center - University of Amsterdam	Recruiting	No outcome recorded
Phase 4	NCT05199038	Jun 2022 → Jun 2023	esophageal varices	Tanta University	Unknown	No outcome recorded
Phase 4	NCT04353193	Jun 2020 → Feb 2022	cirrhosis of liver	Juan A. Arnaiz	Unknown	No outcome recorded
Phase 4	NCT03624517	Sep 2018 → Dec 2024	cirrhosis of liver, esophageal varices with bleeding	Medical University of South Carolina	Terminated	No outcome recorded
Phase 4	NCT03289741	Sep 2017 → Apr 2023	neuroendocrine neoplasm	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 4	NCT04140409	Feb 2016 → Jun 2019	carcinoid syndrome, neuroendocrine neoplasm	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Terminated	No outcome recorded
Phase 4	NCT02032784	Mar 2014 → Jun 2018	adenoma	AdventHealth	Terminated	No outcome recorded
Phase 4	NCT02427295	Mar 2014 → Dec 2018	acromegaly	Asan Medical Center	Unknown	No outcome recorded
Phase 4	NCT01917773	Aug 2013 → Jun 2014	constipation disorder, intestinal motility disease	Indiana University	Completed	No outcome recorded
Phase 4	NCT01618513	Jun 2012 → Jan 2017	acromegaly	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT01301222	Sep 2010 → Sep 2014	pancreas disorder	PVS Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT00552071	Jul 2007 → Mar 2014	acromegaly	Cedars-Sinai Medical Center	Completed	No outcome recorded
Phase 4	NCT01424241	Oct 2006 → Mar 2013	acromegaly	Columbia University	Completed	No outcome recorded
Phase 4	NCT01278342	Sep 2006 → Nov 2009	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00376064	Mar 2006 → Jan 2010	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00171613	Feb → Oct 2005	acquired hypothalamic obesity	Novartis	Completed	No outcome recorded
Phase 4	NCT00076362	Mar 2004 → Jul 2005	obesity disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00108355	Dec 2003 → Aug 2010	cirrhosis of liver	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 4	NCT00068029	Oct 2003 → May 2006	acromegaly	Pfizer	Completed	No outcome recorded
Phase 4	NCT00068042	Apr 2003 → May 2006	acromegaly	Pfizer	Completed	No outcome recorded
Phase 4	NCT00242541	Mar 2003 → Aug 2005	acromegaly	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT00050635	Dec 2002 → Jul 2003	diarrheal disease, neoplasm	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00145405	Sep 2002 → Dec 2004	acromegaly	Odense University Hospital	Completed	No outcome recorded
Phase 4	NCT00171886	Jul 2002 → May 2006	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00521300	Sep 1999 → Jun 2005	acromegaly	St. Olavs Hospital	Completed	No outcome recorded
Phase 4	NCT00461149	Jan 1995 → Dec 2006	acromegaly	Federico II University	Completed	No outcome recorded

Phase not applicable14 trials
—	NCT03891849	Sep 2021 → May 2023	esophageal varices with bleeding	Centre Hospitalier Universitaire, Amiens	Withdrawn	No outcome recorded
—	NCT04522297	Apr 2018 → Jan 2020	hepatorenal syndrome	National Hepatology & Tropical Medicine Research Institute	Completed	No outcome recorded
—	NCT03398941	Feb 2018 → Jan 2019	pancreas disorder	Chengfeng Wang	Unknown	No outcome recorded
—	NCT02381249	Mar 2015 → Mar 2018	gastric neoplasm, neoplasm of esophagus, nutritional disorder, pancreatic neoplasm +1	St. James's Hospital, Ireland	Completed	No outcome recorded
—	NCT02385617	Jan 2014 → Dec 2017	gastric neoplasm, neoplasm of esophagus, nutritional deficiency disease	St. James's Hospital, Ireland	Completed	No outcome recorded
—	NCT02920567	Jan 2014 → Jun 2018	—	Saint Vincent's Hospital, Korea	Unknown	No outcome recorded
—	NCT01865760	Jun 2013 → Mar 2016	hypoglycemia, obesity disorder	University of Aarhus	Completed	No outcome recorded
—	NCT01400100	Aug 2011 → Feb 2012	pancreas disorder	St. Josef Hospital Bochum	Completed	No outcome recorded
—	NCT00652379	Jun 2008 → Nov 2009	acromegaly, glucose intolerance	University of Aarhus	Completed	No outcome recorded
—	NCT06080204	Mar 2008 → Apr 2020	digestive system neuroendocrine tumor, grade 1/2	Changhai Hospital	Completed	No outcome recorded
—	NCT00399893	Dec 2006 → Apr 2009	Prader-Willi syndrome	Duke University	Terminated	No outcome recorded
—	NCT01029275	Jan 2005 → Jan 2012	acromegaly	University Hospital, Rouen	Completed	No outcome recorded
—	NCT00002252	—	HIV infectious disease, diarrheal disease	Sandoz	Completed	No outcome recorded
—	NCT00002253	—	HIV infectious disease, diarrheal disease	Sandoz	Completed	No outcome recorded

Also used as a comparator or background therapy in 69 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT03520569 Comparator	Feb 2019 → Apr 2021	arterial disorder	University of Virginia	Completed	No outcome recorded
Phase 115 trials
Phase 1	NCT06558422 Background	Jan 2027 → Dec 2028 expected	hyperinsulinism, metabolic dysfunction-associated steatotic liver disease, obesity disorder, prediabetes syndrome	Columbia University	Not yet recruiting	No outcome recorded
Phase 1	NCT06881888 Comparator	Aug 2026 → Dec 2027 expected	diabetic macular edema	University of Alabama at Birmingham	Not yet recruiting	No outcome recorded
Phase 1	NCT07663318 Comparator	Jun → Jul 2026 overdue	acromegaly	Triastek (Shanghai) Limited	Not yet recruiting	No outcome recorded
Phase 1	NCT06592261 Background	Sep 2024 → Aug 2026 overdue	hyperinsulinism, obesity disorder	Columbia University	Recruiting	No outcome recorded
Phase 1	NCT06126354 Background	Jul 2024 → Nov 2025	NAFLD1, prediabetes syndrome	Columbia University	Withdrawn	No outcome recorded
Phase 1	NCT05724134 Background	Aug 2023 → Sep 2025	NAFLD1, hyperinsulinism, obesity disorder, prediabetes syndrome	Columbia University	Completed	No outcome recorded
Phase 1	NCT05364944 Background	May 2022 → Oct 2024	acromegaly, digestive system neuroendocrine neoplasm	Debiopharm International SA	Terminated	No outcome recorded
Phase 1	NCT03879694 Background	Jun 2019 → Feb 2025	atypical carcinoid tumor, lung carcinoid tumor, pancreatic neuroendocrine tumor	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1	NCT03057509 Background	Nov 2018 → Oct 2019	carcinoid tumor	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 1	NCT03571594 Comparator	Jun 2018 → May 2019	acromegaly	Ono Pharmaceutical Co., Ltd.	Terminated	No outcome recorded
Phase 1	NCT02237053 Comparator	Sep 2014 → Jun 2015	abnormality of glucagon secretion, obesity disorder	AdventHealth Translational Research Institute	Completed	No outcome recorded
Phase 1	NCT01871844 Comparator	Jan → Sep 2012	—	Italfarmaco	Completed	No outcome recorded
Phase 1	NCT01204476 Background	Oct 2010 → Jul 2014	PPoma, cutaneous neuroendocrine carcinoma, gastrin-producing neuroendocrine tumor, glucagonoma +5	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01561066 Comparator	Jan 2008 → Jan 2012	intestinal fistula	Jinling Hospital, China	Completed	No outcome recorded
Phase 1	NCT02012166 Background	Jul → Dec 2005	type 2 diabetes mellitus	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase 214 trials
Phase 2	NCT06865677 Background	Jun → Jul 2025	cervical carcinoma, endometrial carcinoma, ovarian carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT06326190 Comparator	Mar 2025 → Apr 2027 expected	meningioma	European Organisation for Research and Treatment of Cancer - EORTC	Recruiting	No outcome recorded
Phase 2	NCT06505395 Comparator	Jul 2024 → Aug 2027 expected	digestive system neuroendocrine neoplasm	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT04941911 Comparator	May 2022 → Oct 2023	kidney failure	University College, London	Unknown	No outcome recorded
Phase 2	NCT04048707 Comparator	Jul 2021 → Jun 2023	acute kidney injury, cirrhosis of liver, hepatorenal syndrome	University of California, Los Angeles	Withdrawn	No outcome recorded
Phase 2	NCT03967249 Background	Jul 2019 → Mar 2022	acromegaly	Ionis Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02795858 Background	Jun 2016 → Dec 2022	carcinoid tumor	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT02736448 Background	May 2016 → Aug 2019	digestive system neuroendocrine neoplasm	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Terminated	No outcome recorded
Phase 2	NCT02111044 Comparator	Apr 2014 → Feb 2016	acromegaly	Italfarmaco	Completed	No outcome recorded
Phase 2	NCT01157858 Comparator	Jun 2010 → Jul 2012	liver disorder	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00853047 Background	Mar 2009 → Jun 2014	carcinoid syndrome	Lexicon Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00427349 Background	Nov 2008 → Oct 2014	carcinoid tumor, digestive system neuroendocrine neoplasm, neoplastic syndrome	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 2	NCT00363051 Background	Jun 2006 → Jan 2008	pancreatic endocrine carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00466856 Background	Dec 2003 → Oct 2006	head and neck cancer, metastatic malignant neoplasm, pancreatic neuroendocrine tumor, pheochromocytoma	Vanderbilt-Ingram Cancer Center	Terminated	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT04329039 Comparator	Nov 2020 → May 2027	pancreas disorder	Mayo Clinic	Suspended	No outcome recorded
Phase 2/3	NCT01744249 Background	Nov 2011 → Dec 2023	neuroendocrine neoplasm	Spanish Group for Research in Neuroendocrine Tumors	Completed	No outcome recorded
Phase 2/3	NCT00426153 Comparator	Jan 2007 → Oct 2008	autosomal dominant polycystic kidney disease, autosomal dominant polycystic liver disease	Mayo Clinic	Completed	No outcome recorded
Phase 317 trials
Phase 3	NCT06878664 Background	Jun 2025 → Jan 2029 expected	intestinal neuroendocrine neoplasm	Spanish Group for Research in Neuroendocrine Tumors	Recruiting	No outcome recorded
Phase 3	NCT07057622 Comparator	Dec 2023 → Nov 2026 expected	—	HTA Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT05884255 Comparator	Jul 2023 → Dec 2026 expected	digestive system neuroendocrine neoplasm	Jiangsu HengRui Medicine Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT05459844 Comparator	Aug 2022 → Jun 2024 overdue	neuroendocrine neoplasm	Sinotau Pharmaceutical Group	Active not recruiting	No outcome recorded
Phase 3	NCT05477576 Comparator	Mar 2022 → Dec 2026 expected	carcinoid tumor, pancreatic neuroendocrine tumor	RayzeBio, Inc.	Recruiting	No outcome recorded
Phase 3	NCT03972488 Comparator	Jan 2020 → Jul 2023 overdue	digestive system neuroendocrine neoplasm	Advanced Accelerator Applications	Active not recruiting	No outcome recorded
Phase 3	NCT03252353 Comparator	Sep 2017 → Jun 2019	acromegaly	Chiasma, Inc.	Unknown	No outcome recorded
Phase 3	NCT03000946 Comparator	May 2017 → Feb 2021	pancreas disorder	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02384122 Comparator	Sep 2015 → Jul 2022	anemia, angiodysplasia, vascular malformation	Radboud University Medical Center	Completed	No outcome recorded
Phase 3	NCT02457156 Background	Apr 2015 → Jul 2018	malignant pancreatic neoplasm	University of Liverpool	Completed	No outcome recorded
Phase 3	NCT01137682 Comparator	Jul 2010 → Jan 2013	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00765323 Comparator	Sep 2008 → Feb 2011	acromegaly	Endo USA Inc., a Keenova Therapeutics Company	Terminated	No outcome recorded
Phase 3	NCT00690430 Comparator	Apr 2008 → Apr 2012	carcinoid syndrome	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00600886 Comparator	Feb 2008 → Mar 2016	acromegaly	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00616551 Comparator	Apr 2007 → Feb 2008	acromegaly	Ambrilia Biopharma, Inc.	Completed	No outcome recorded
Phase 3	NCT00412061 Background	Dec 2006 → Apr 2010	carcinoid syndrome, carcinoid tumor	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00002864 Comparator	Sep 1996 → Dec 2007	breast cancer	NCIC Clinical Trials Group	Completed	No outcome recorded

Phase 411 trials
Phase 4	NCT06974344 Comparator	Jun 2025 → May 2030 expected	—	King Faisal Specialist Hospital & Research Center	Not yet recruiting	No outcome recorded
Phase 4	NCT05701241 Comparator	Jun 2023 → Apr 2029 expected	digestive system neuroendocrine neoplasm	University Hospital, Antwerp	Recruiting	No outcome recorded
Phase 4	NCT05682209 Comparator	Dec 2020 → Nov 2021	—	Ikechukwu Bartholomew Ulasi	Completed	No outcome recorded
Phase 4	NCT04028323 Comparator	Jul 2019 → Jul 2020	esophageal varices with bleeding, impaired renal function disease	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT03455322 Comparator	Aug 2018 → Apr 2020	hepatorenal syndrome	National Hepatology & Tropical Medicine Research Institute	Completed	No outcome recorded
Phase 4	NCT02119884 Comparator	Feb 2014 → Jun 2016	varicose disease	Shanghai Zhongshan Hospital	Completed	No outcome recorded
Phase 4	NCT01789281 Background	May 2013 → Aug 2020	neoplasm	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00595140 Comparator	Jan → Mar 2008	acromegaly	Ludwig-Maximilians - University of Munich	Completed	No outcome recorded
Phase 4	NCT00966355 Comparator	Sep 2006 → May 2010	esophageal varices with bleeding	Korea University	Completed	No outcome recorded
Phase 4	NCT00534677 Comparator	May 2004 → Jul 2005	cirrhosis of liver, esophageal varices with bleeding, portal hypertension	Aga Khan University	Completed	No outcome recorded
Phase 4	NCT01371643 Comparator	Apr 2004 → Jul 2010	pituitary gland adenoma	NYU Langone Health	Completed	No outcome recorded

Phase not applicable8 trials
—	NCT07460908 Comparator	May → Oct 2025	hepatorenal syndrome	Lahore General Hospital	Completed	No outcome recorded
—	NCT03061604 Background	Nov 2014 → Nov 2017	varicose disease	Theodor Bilharz Research Institute	Completed	No outcome recorded
—	NCT02474914 Comparator	May 2014 → Apr 2017	carcinoma	Mansoura University	Completed	No outcome recorded
—	NCT02123576 Background	Apr 2014 → Dec 2017	hepatorenal syndrome	Patrick Northup, MD	Terminated	No outcome recorded
—	NCT02010385 Comparator	Feb 2013 → Jun 2018	—	University College Dublin	Completed	No outcome recorded
—	NCT01538966 Comparator	Mar 2012 → May 2022	acromegaly	Cedars-Sinai Medical Center	Terminated	No outcome recorded
—	NCT02305069 Background	Oct 2009 → Oct 2011	muscular atrophy, obesity disorder	University of Nottingham	Completed	No outcome recorded
—	NCT01613495 Comparator	Aug 2005 → Mar 2024	Prader-Willi syndrome	Oregon Health and Science University	Unknown	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2024-10-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. tevapharm.com ↗

Evidence & citations 33 cited values

Every value below carries the sentence it was read from. 229 sources stand behind the page.

Field	Value	Cited text
Known as	Octreotide	“Octreotide, an analog of somatostatin, a synthetic form of the hypothalamic hormone somatostatin, which inhibits growth hormone (GH) release by blocking somatostatin receptors...” NCT01424241 ↗ 179 “Patients were randomly assigned (1:1) to axitinib 5 mg or placebo, both orally twice a day, in combination with intramuscular octreotide long-acting release 30 mg once every 28...” PMID 41719493 ↗ Feb 2026 “In total, 136 patients will be randomized in a 2:1 ratio to [177Lu]Lu-DOTATATE (≤4 doses of 7.4 GBq given every 4 wk) or local standard of care (hydroxyurea, bevacizumab,...” PMID 40774695 ↗ Jan 2026 “The medical treatment is based on proglycem, or diazoxide, then octreotide (Sandostatine ®, Novartis) with a dose of 10 to 50 µg/Kg/jour divided to three subcutaneous injections.” NCT00987168 ↗ “Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.” PMID 38662619 ↗ Apr 2024 “Somatostatin analog (octreotide long-acting release (LAR) 30 mg or lanreotide 120 mg) will be given every four weeks for a duration of 18 months.” NCT05701241 ↗ “A pilot study suggested that the somatostatin analogue octreotide longacting release (LAR) could be nephroprotective in this context.” PMID 23972263 ↗ Aug 2013 “Antibiotics along with octreotide, which works by inhibiting pancreatic secretions, is standard treatment for a pancreatic fistula.” NCT04329039 ↗ “The active ingredient in CAM2029, octreotide, is administered as a subcutaneous depot using Camurus' FluidCrystal® technology.” NCT05281328 ↗ “The somatostatin analogue octreotide (Sandostatin®, Novartis) contains 8 amino acids and is very similar to SST-14.” NCT00175305 ↗ “CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection” NCT05050942 ↗ “Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort.” NCT07623824 ↗ “Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.” NCT03967249 ↗ “whether it is affected by the treatment with the somatostatin analogue, octreotide.” NCT02119052 ↗ “either SYHX2008（octreotide long-acting injection) or placebo at dose of 5 mg” NCT05761431 ↗ “a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR” NCT00635765 ↗ “Albumin, midodrine and octreotide therapy (standard of care for HRS)” NCT02123576 ↗ “Octreotide subcutaneous: 0,1 mg every 8 hours during maximum 7 days” NCT07262957 ↗ “IM injection, a 12-week extended-release formulation of octreotide” NCT06930625 ↗ “treatment with the somatostatin analogue, octreotide.” NCT02119013 ↗ “Octreotide Microspheres (Sandostatin LAR@)” NCT06505395 ↗ “long acting octreotide or lanreotide” NCT02736448 ↗ “6. SSTR2: Octreotide” NCT02101385 ↗ “octreotide” NCT02795858 ↗ NCT05199038 ↗ NCT00690430 ↗ NCT02668588 ↗ NCT00002967 ↗ NCT00004895 ↗ NCT00128232 ↗ NCT00033605 ↗ NCT00990535 ↗ NCT06062719 ↗ NCT01377246 ↗ NCT04027348 ↗ NCT01029275 ↗ NCT00804297 ↗ NCT04076462 ↗ NCT02920567 ↗ NCT00372697 ↗ NCT02685709 ↗ NCT00595140 ↗ NCT03455322 ↗ NCT06878664 ↗ NCT07165886 ↗ NCT03541447 ↗ NCT01371643 ↗ NCT06085976 ↗ NCT04048707 ↗ NCT01412424 ↗ NCT00145405 ↗ NCT00006269 ↗ NCT00171886 ↗ NCT05724134 ↗ NCT02916433 ↗ NCT00652379 ↗ NCT04125836 ↗ NCT00166725 ↗ NCT01613495 ↗ NCT00131144 ↗ NCT04353193 ↗ NCT05477576 ↗ NCT00466856 ↗ NCT00274170 ↗ NCT00171873 ↗ NCT00884715 ↗ NCT05884255 ↗ NCT02874326 ↗ NCT02474914 ↗ NCT00412061 ↗ NCT01137682 ↗ NCT00225979 ↗ NCT00004327 ↗ NCT00332969 ↗ NCT00426153 ↗ NCT02381249 ↗ NCT01917773 ↗ NCT00600886 ↗ NCT06974344 ↗ NCT03289741 ↗ NCT02217800 ↗ NCT02294006 ↗ NCT00427349 ↗ NCT03398941 ↗ NCT00332696 ↗ NCT00582426 ↗ NCT05683444 ↗ NCT00742339 ↗ NCT02385617 ↗ NCT01295060 ↗ NCT00853047 ↗ NCT05682209 ↗ NCT01203306 ↗ NCT03798912 ↗ NCT06080204 ↗ NCT04522297 ↗ NCT04941911 ↗ NCT02010385 ↗ NCT03061604 ↗ NCT04028323 ↗ NCT01188733 ↗ NCT00003283 ↗ NCT03972488 ↗ NCT00616551 ↗ NCT01480986 ↗ NCT00262470 ↗ NCT01204476 ↗ NCT04871204 ↗ NCT00005906 ↗ NCT02111044 ↗ NCT00399893 ↗ NCT02294786 ↗ NCT07460908 ↗ NCT02237053 ↗ NCT02409849 ↗ NCT00241020 ↗ NCT02384122 ↗ NCT00182754 ↗ NCT02032784 ↗ NCT01707225 ↗ NCT05340192 ↗ NCT03179995 ↗ NCT00257426 ↗ NCT00386984 ↗ NCT00463983 ↗ NCT00003057 ↗ NCT02437825 ↗ NCT02305069 ↗ NCT00088582 ↗ NCT01400100 ↗ NCT03252353 ↗ NCT00240045 ↗ NCT00376064 ↗ NCT07057622 ↗ NCT03057509 ↗ NCT00521300 ↗ NCT06865677 ↗ NCT02427295 ↗ NCT00171613 ↗ NCT00002864 ↗ NCT00170742 ↗ NCT02119884 ↗ NCT00223691 ↗ NCT01865760 ↗ NCT05459844 ↗ NCT03624517 ↗ NCT00008073 ↗ NCT03571594 ↗ NCT00966355 ↗ NCT00002252 ↗ NCT00002253 ↗ NCT00250796 ↗ NCT02235987 ↗ NCT06881888 ↗ NCT00130845 ↗ NCT01561066 ↗ NCT02457156 ↗ NCT00953394 ↗ NCT00248157 ↗ NCT00765323 ↗ NCT03879694 ↗ NCT00002779 ↗ NCT03891849 ↗ NCT03520569 ↗ NCT02217826 ↗ NCT00248131 ↗ NCT01587222 ↗ NCT00495846 ↗ NCT00113360 ↗ NCT01301222 ↗ NCT00552071 ↗ NCT01871844 ↗ NCT04129255 ↗ NCT02333565 ↗ NCT00534677 ↗ NCT00913055 ↗ NCT02217839 ↗ NCT02299089 ↗ NCT00432068 ↗ NCT03031535 ↗
Known as	C2L-OCT-01 PR	“a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR” NCT00635765 ↗
Known as	CAM2029	“CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection” NCT05050942 ↗
Known as	LAO	“METHODS: A randomized, double-blinded, placebo-controlled trial was designed to determine the efficacy of long-acting octreotide acetate (LAO) in preventing the onset of acute...” PMID 20339140 ↗ Mar 2010
Known as	LAR octreotide	“LAR octreotide (20 mg monthly)” PMID 19886987 ↗ Nov 2009
Known as	Long-acting octreotide	“long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks” NCT00953394 ↗ 1 “Long-acting octreotide” NCT01188733 ↗
Known as	Mycapssa	“Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®)” NCT07663318 ↗
Known as	OCLAR	“Individually tailored octreotide LAR (OCLAR) was administered.” PMID 16449332 ↗ Jan 2006
Known as	OCT	“Octreotide (OCT) has been successfully used for treatment of acromegaly and neuroendocrine tumors for more than 30 years.” PMID 29116540 ↗ Nov 2017 1 “Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation” NCT00990535 ↗
Known as	octLAR	“Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).” PMID 35724357 ↗ Jun 2022 2 “the slow-release form of octreotide (OCT; Sandostatin LAR, OCT-LAR), for im injection every 28 days” PMID 10999798 ↗ Sep 2000 “octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth” PMID 22773240 ↗ Jul 2012
Known as	Octreotide Acetate	“The purpose of the study is to investigate the drug octreotide acetate in a new intranasal formulation and compare it to the FDA-approved subcutaneous (SC) injection formulation.” NCT03031535 ↗ 23 “Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®)” NCT07663318 ↗ “long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks” NCT01203306 ↗ “a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR” NCT00635765 ↗ “Octreotide acetate 30 mg suspension” NCT00372697 ↗ “Octreotide acetate in microspheres” NCT00248131 ↗ “Sandostatin (Octreotide Acetate)” NCT02427295 ↗ “Drug: Octreotide Acetate” NCT04941911 ↗ “Drug: octreotide acetate” NCT00913055 ↗ “Drug: octreotide acetate” NCT00182754 ↗ “Drug: octreotide acetate” NCT00002779 ↗ “Drug: Octreotide Acetate” NCT04129255 ↗ “Drug: octreotide acetate” NCT00033605 ↗ NCT00227773 ↗ NCT01469338 ↗ NCT06126354 ↗ NCT06592261 ↗ NCT06558422 ↗ NCT02195635 ↗ NCT00242541 ↗ NCT00569127 ↗ NCT01229943 ↗ NCT00075868 ↗ NCT01086982 ↗
Known as	Octreotide acetate LAR	“Octreotide acetate LAR 30 MG” NCT01086982 ↗
Known as	Octreotide Depot	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00363051 ↗
Known as	Octreotide LAR	“Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular...” NCT03972488 ↗ 19 “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut...” PMID 19704057 ↗ Aug 2009 “Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week.” PMID 28384065 ↗ Apr 2017 “Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。” NCT06080204 ↗ “to 3 year treatment with two 20 mg intramuscular injections of octreotide-LAR (n=40) or 0·9% sodium chloride solution (n=39) every 28 days.” PMID 23972263 ↗ Aug 2013 “Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)” NCT00002864 ↗ “NCIC CTG MA.14 and NSABP B-29 trials examined the addition of Octreotide LAR (OCT) to 5 years of tamoxifen (TAM).” PMID 26276354 ↗ Aug 2015 “Octreotide LAR is approved for treatment of acromegaly after surgery if the disease is not controlled.” NCT00128232 ↗ “Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection” NCT05050942 ↗ “long-acting somatostatin analogue (Octreotide LAR) compared with placebo” NCT01377246 ↗ “primary octreotide LAR, lanreotide SR, or sc octreotide therapy” PMID 15886238 ↗ May 2005 “plus Octreotide LAR (20 mg monthly)” NCT00953394 ↗ NCT00461149 ↗ NCT01538966 ↗ NCT01567488 ↗ NCT01157858 ↗ NCT00108355 ↗ NCT01578239 ↗ NCT01886287 ↗ NCT06784752 ↗
Known as	octreotide long-acting release	“Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).” PMID 35724357 ↗ Jun 2022 1 “OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)” NCT04129255 ↗
Known as	octreotide longacting release (LAR)	“A pilot study suggested that the somatostatin analogue octreotide longacting release (LAR) could be nephroprotective in this context.” PMID 23972263 ↗ Aug 2013
Known as	Octreotide Microspheres	“Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort.” NCT07623824 ↗ 1 “Octreotide Microspheres (Sandostatin LAR@)” NCT06505395 ↗
Known as	octreotide pamoate	“octreotide pamoate (SMS 201-995 pa LAR) intramuscularly (IM) every 21 days for 4 doses” NCT00002967 ↗
Known as	octreotide-long-acting repeatable	“Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients” PMID 12843148 ↗ Jul 2003
Known as	Sandostatin	“The other 2 cohorts are octreotide long-acting release ( Sandostatin LAR® ) 20 mg and Sandostatin® 0.1 mg.” NCT05761431 ↗ 6 “100 mcg of octreotide (Sandostatin®) will be injected intravenously.” NCT03798912 ↗ “Sandostatin (Octreotide Acetate)” NCT02427295 ↗ NCT00050635 ↗ NCT00510224 ↗ NCT00092287 ↗ NCT04140409 ↗
Known as	Sandostatin LAR	“Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。” NCT06080204 ↗ 13 “Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide.” NCT02294786 ↗ “The other 2 cohorts are octreotide long-acting release ( Sandostatin LAR® ) 20 mg and Sandostatin® 0.1 mg.” NCT05761431 ↗ “the slow-release form of octreotide (OCT; Sandostatin LAR, OCT-LAR), for im injection every 28 days” PMID 10999798 ↗ Sep 2000 “Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort.” NCT07623824 ↗ “the first dose of long-acting octreotide (Sandostatin LAR) depot will be given intramuscularly” NCT00257426 ↗ “Sandostatin LAR ® (octreotide acetate LAR) 30 MG” NCT01086982 ↗ “Octreotide Microspheres (Sandostatin LAR@)” NCT06505395 ↗ NCT01618513 ↗ NCT00076362 ↗ NCT05364944 ↗ NCT01278342 ↗ NCT00068029 ↗ NCT00068042 ↗
Known as	Sandostatin LAR (Registered Trademark) Depot	“The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients...” NCT00001860 ↗
Known as	Sandostatin LAR Depot	“Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular...” NCT03972488 ↗ 7 “A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity...” NCT00075868 ↗ “The purpose of this study is to learn more about how octreotide (Sandostatin LAR® Depot) affects levels of ghrelin, hunger, and body weight in people with Prader-Willi Syndrome.” NCT01613495 ↗ “Subjects were allowed to continue combination therapy with Sandostatin LAR® Depot if they were receiving this combination therapy on the parent protocol.” NCT01789281 ↗ NCT00001860 ↗ NCT00094146 ↗ NCT01121939 ↗ NCT01789281 ↗
Known as	Sandostatin LP	“patients with IPF will receive an intramuscular injection of slow release octreotide (Sandostatin LP, 30 mg)every 4 weeks for 48 weeks.” NCT00463983 ↗
Known as	Sandostatine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02012166 ↗
Known as	SMS 201-995 pa LAR	“Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)” NCT00002864 ↗ 1 “octreotide pamoate (SMS 201-995 pa LAR) intramuscularly (IM) every 21 days for 4 doses” NCT00002967 ↗
Known as	SMS995	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00584298 ↗
Known as	Somatostatin	“Somatostatin (octreotide)” NCT00386984 ↗
Known as	SYHX2008	“either SYHX2008（octreotide long-acting injection) or placebo at dose of 5 mg” NCT05761431 ↗
Known as	T25	“Orally Administrated Octreotide Acetate Tablets (T25) and Orally Administrated Octreotide Acetate Delayed-Release Capsules (MYCAPSSA®)” NCT07663318 ↗
Action	Inhibit	“Octreotide Depot may also help to block certain proteins that are important in tumor growth.” NCT00113360 ↗
Modality	Peptide	“octreotide, a somatostatin octapeptide analog” NCT00004327 ↗
Route	Subcutaneous	“receive a test dose of octreotide subcutaneously on day 1” NCT00002779 ↗